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Abstract 
Background: Virus-like particles (VLPs) of the RNA bacteriophage MS2 have many potential applications in biotech-
nology. MS2 VLPs provide a platform for peptide display and affinity selection (i.e. biopanning). They are also under 
investigation as vehicles for targeted drug delivery, using display of receptor-specific peptides or nucleic acid aptam-
ers to direct their binding to specific cell-surface receptors. However, there are few molecules more suited to the 
precise targeting and binding of a cellular receptor than antibodies.
Results: Here we describe a strategy for display of four different functional single-chain variable fragments (scFvs) on 
the surface of the MS2 VLP. Each scFv is validated both for its presence on the surface of the VLP and for its ability to 
bind its cognate antigen.
Conclusions: This work demonstrates the suitability of the MS2 VLP platform to display genetically fused scFvs, allow-
ing for many potential applications of these VLPs and paving the way for future work with libraries of scFvs displayed 
in a similar manner on the VLP surface. These libraries can then be biopanned and novel scFv binders to targets can 
be readily discovered.
Keywords: Virus-like particles, Phage display, Single-chain antibodies, Bacteriophage MS2
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Virus-like particles (VLPs) are finding diverse applica-
tions in nanobiotechnology, including as targeted drug 
delivery vehicles (see Ref. [1] for a recent review) and 
imaging agents (for some examples see Refs. [2–5]). 
Some applications, especially those requiring the VLP be 
directed to abnormal cells within a population of healthy 
cells, require the VLP to recognize receptors on specific 
cell types. Targeting can be mediated by decoration of 
the surface of the VLP with a peptide [6] or nucleic acid 
aptamer [7] specific for a receptor on the cell surface. 
Antibodies have also been utilized for this application 
[8–11] and can sometimes offer affinity and specificity 
advantages over other targeting moieties. Furthermore, 
a large number of antibodies with known specificities 
for diverse receptors have already been characterized, 
providing a rich source of potential targeting molecules. 
Single-chain variable fragments (scFvs) are modified ver-
sions of full antibodies that contain the antigen binding 
site, but they are also more amenable to genetic manipu-
lation than the intact antibody because they are smaller 
and are comprised of a single polypeptide chain. Further, 
the absence of a fragment crystallizable (Fc) region helps 
prevent unwanted off-target binding to cells with Fc-
receptors. Antibodies can be attached to a drug delivery 
vehicle (e.g. a VLP) by chemical conjugation [8–11], but 
display by genetic fusion to a VLP structural protein is an 
attractive alternative. Not only does genetic fusion offer 
production advantages, but at least in the case of the bac-
teriophage MS2 system described here (and previously 
described, see Refs. [12–14]), the VLP encapsidates the 
RNA that encodes it. The MS2 VLP platform has already 
been developed for display and affinity selection from 
random peptide libraries [12].
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Here we describe the functional display of four genet-
ically-fused scFvs on MS2 VLPs. The work presented 
here paves the way for display of random scFv librar-
ies on the MS2 VLP, allowing for identification of scFvs 
with new binding affinities by biopanning directly on the 
VLP itself. Because of the simplicity of the MS2 VLP, the 
creation and biopanning of the scFv-MS2 library could 
be accomplished entirely in  vitro, allowing for greater 
library complexities and faster selection/production than 
many other scFv display platforms.
Methods
Plasmids and proteins
Plasmids pDSP1, pDSP62 and their derivatives have been 
previously described [15]. The new constructs described 
here were made using standard molecular biology meth-
ods and have the characteristics described here.
Each of the coat protein-scFv fusions was constructed 
using pDSP62AP, whose principle features are illustrated 
in Fig. 1a. The plasmid expresses coat protein in bacteria 
as a single-chain dimer [12, 13, 15–18] and confers resist-
ance to kanamycin. The coat sequence is terminated with 
a single amber codon which is immediately followed by 
PstI and BamHI sites. Each of the scFvs utilized in these 
studies was assembled from synthetic oligonucleotides 
by Gibson assembly [19] and was flanked by BamHI and 
PstI sites for facile insertion into pDSP62AP. The scFv 
sequences were designed so that suppression of the stop 
codon results in the production of a coat protein single-
chain dimer fused through an oligoglycine linker to the 
scFv. Low level stop codon suppression (a few percent) 
was promoted by an alanine-inserting amber-suppressing 
tRNA [20] expressed from the lac promoter on pNM-
supA, a pACYC184 derivative [21]. A similar plasmid, 
pNMsupS2, expresses a serine-inserting amber-suppress-
ing tRNA based on the E. coli supD mutation [20, 22] and 
suppresses at high efficiency. We introduced an A → G 
mutation in the anticodon loop to reduce its suppression 
efficiency to a few percent. Since the suppressor-tRNA-
producing plasmids represent a different incompatibility 
group, and because they confer resistance to a different 
antibiotic (chloramphenicol), they can be stably main-
tained in cells also containing pDSP62AP derivatives.
Proteins were produced by expression in E. coli strain 
C41(DE3) (Lucigen) and the resulting VLPs were puri-
fied by Sepharose CL4B column chromatography as 
previously described [13]. Purity of VLPs was assessed 
by electrophoresis on polyacrylamide gels (17.5%) in 
the presence of sodium dodecyl sulfate and by electro-
phoresis of the intact particle on 1% phosphate agarose 
gels. SDS gels were stained with Coomassie brilliant blue 
R250 and the proteins in duplicate gels were transferred 
to nitrocellulose membranes and probed with rabbit 
anti-MS2 serum and an alkaline phosphatase-conjugated 
goat anti-rabbit IgG secondary antibody. Agarose gels 
were stained with ethidium bromide to reveal the pres-
ence of the RNA-containing VLPs.
ELISA
To determine whether the anthrax protective antigen-
specific scFv M18 was functionally displayed on the VLP 
surface, it was assayed for its ability to mediate interac-
tion of the VLP with protective antigen in ELISA. Wells 
of an Immulon 2 ELISA plate (Thermo Scientific) were 
coated with 500  ng of anthrax protective antigen (Inv-
itrogen) by incubation at 4  °C overnight in PBS. Wells 
were blocked for 2 h at room temperature (RT) with 0.5% 
non-fat dry milk in PBS buffer, and then serial dilutions 
of either WT or M18-expressing VLPs were added to 
each well and incubated for 2 h at RT. Mouse anti-MS2 
serum was added at a 1:2000 dilution to each well and 
incubated for 2 h at RT. After washing with PBS, the wells 
were incubated for 1 h at RT with horseradish peroxidase 
(HRP)-conjugated goat anti-mouse IgG at a 1:5000 dilu-
tion. After washing, the plates were developed with the 
chromogenic substrate 2,2′-azino-bis(3-ethylbenzthia-
zoline-6-sulfonic acid) (ABTS), and after sufficient color 
development, optical density at 405 nm was measured.
Mammalian cell culture
Cell lines, media, and supplements were obtained from 
ATCC and cultivated according to the supplier’s instruc-
tions. Hep3B cells were maintained in culture plates in 
EMEM with 10% FBS. Thle-3 cells were grown in plates 
coated with BSA, fibronectin, and bovine collagen type 
I. The culture medium used was BEGM (gentamicin, 
amphotericin, and epinephrine were discarded from the 
BEGM Bullet kit) with 5 ng/mL epidermal growth factor, 
70 ng/mL phosphatidylethanolamine, and 10% FBS. Vero 
cells (CCL-81) were maintained in DMEM with 10% FBS, 
and were passaged after treatment with 0.25% trypsin at a 
sub-cultivation ratio of 1:10. All cells were maintained at 
37 °C in a humidified atmosphere (air supplemented with 
6% CO2) and were passaged after treatment with 0.05% 
trypsin at a sub-cultivation ratio of 1:7.
Fluorescence activated cell sorting (FACS)
VLPs (WT and AF-20) were labeled with Alexa Fluor 488 
NHS ester (Invitrogen) on surface amines according to 
the manufacturer’s instructions. To reduce non-specific 
interactions with cells, VLPs were also derivatized at 
surface carboxyl groups using EDC (Pierce) and an ami-
nated polyethylene glycol (PEG) 12mer. Cells (1 ×  106) 
were exposed to increasing amounts of VLPs (4 ×  1012 
to 4  ×  1015, roughly 16  μg  to  16  mg) for 1  h at 37  °C. 
Cells were then pelleted and washed in FACS buffer (1× 
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PBS, 1% BSA, pH 7.4) before being fixed with 3.7% for-
maldehyde and resuspended in FACS buffer. They were 
immediately analyzed with a FACSCalibur flow cytom-
eter (Becton–Dickinson) equipped with BD CellQuest 
software at the UNM Shared Flow Cytometry and High 
Throughput Screening Resource. Data were acquired 
with the FSC channel in linear mode and all other chan-
nels in log mode. Events were triggered based upon for-
ward light scatter, and a gate was placed on the forward 
scatter-side scatter plot that excluded cellular debris. 
Samples were excited using the 488-nm laser source, 
and emission intensity was collected in the FL1 channel 
(530/30). Fluorescence intensity was determined using 
the BD CellQuest software and data were plotted using 
Graphpad Prism.
Confocal microscopy
1 × 106 cells/mL of either Hep3B or Thle-3 were seeded 
on sterile coverslips (25-mm, No. 1.5) coated with 0.01% 
poly-l-lysine and allowed to adhere for 4–24 h at 37 °C. 
10 μg (~2.4 × 1012 particles) of either WT or AF-20 VLPs 
were incubated with the cells for 2  h at 37  °C, washed 
three times with 1× PBS, fixed with 3.7% formalde-
hyde (10 min at RT), and mounted with SlowFade Gold. 
Prior to fixation, cells were stained with CellTracker Red 
CMFDA (Invitrogen) to visualize cytoplasm and Hoe-
chst 33342 (Invitrogen) to visualize the nucleus. Three-
color images were acquired using a Zeiss LSM510 META 
(Carl Zeiss MicroImaging, Inc.) operated in Channel 
mode of the LSM510 software; a 63×, 1.4-NA oil immer-
sion objective was employed in all imaging. Typical laser 
power settings were: 30% transmission for the 405-nm 
diode laser, 5% transmission (60% output) for the 488-
nm Argon laser, 100% transmission for the 543-nm HeNe 
laser, and 85% transmission for the 633-nm HeNe laser. 
Gain and offset were adjusted for each channel to avoid 
saturation and were typically maintained at 500–700 and 
−0.1, respectively. 8-bit z-stacks with 1024 × 1024 reso-
lutions were acquired with a 0.7 to 0.9-μm optical slice. 
LSM510 software was used to overlay channels and to 
create 3D projections of z-stack images.
Neutralization of Nipah‑VSV pseudotype
Neutralization assays were performed using the method 
of Tamin et al. [23]. Briefly, Vero cells were grown in cul-
ture flasks to approximately 80% confluence and passaged 
after treatment with 0.25% trypsin. Cells were seeded in 
DMEM with 10% FBS onto pre-treated 96-well plates at 
a concentration of 8000 cells/well and allowed to adhere 
for approximately 18  h at 37  °C. VLP samples starting 
at a concentration of 1 µg/µl (1.3 ×  1012 total particles) 
were diluted fourfold serially, and each was incubated for 
30  min at room temperature with a VSV recombinant 
virus pseudotyped with NiV G- and F-protein and 
expressing Renilla luciferase (NiVpp). The pseudotype-
serum mixture was then added to the adhered Vero cells 
in the 96 well plate, and the cells were incubated with the 
mixture for 90 min at 37 °C. Cells were then washed three 
times with 1× D-PBS and 150 µl of DMEM with 10% FBS 
were added. After incubation for 18 h at 37 °C, cells were 
washed three times with 1× D-PBS, and then lysed and 
assayed for luciferase activity using the Renilla Luciferase 
Assay System (E2810) (Promega). Luminosity was read 
with a luminometer integrated over 10 s with a 2 s delay.
Results
We chose four different scFvs to test the display capa-
bilities of MS2 VLPs. One, called M18, recognizes the 
protective antigen (PA) of anthrax [24] and is based the 
nucleotide sequence given by Young and Collier [25]. 
Another, called scFv AF-20, is specific for a protein (AF-
20) found abundantly on hepatocellular carcinoma cells 
(HCC) but not on hepatocytes [10]. We synthesized the 
anti-AF-20 scFv (henceforth referred to only as AF-20 
for clarity within the text) from the nucleotide sequence 
given by Yeung [26]. Two other scFvs were derived from 
antibodies specific for proteins of Nipah virus. One 
(scFv26) recognizes the viral envelope (or G) protein 
[27], and the other (scFv66) binds the viral fusion (or F) 
protein [28]. Both anti-Nipah scFvs were based on pre-
viously described monoclonal antibodies [29]. All scFv 
coding sequences were synthesized by assembly PCR 
from synthetic oligonucleotides [19]. Each was flanked 
by unique PstI and BamHI sites for facile insertion into 
pDSP62AP (Fig. 1) and fusion to the coat protein C-ter-
minus. We utilized the single-chain dimer version of coat 
protein [12, 16–18] because its higher thermodynamic 
stability makes it more tolerant of a variety of mutational 
perturbations, including peptide fusions and insertions.
From the outset, we assumed that high-level synthesis 
of the coat-scFv fusion protein would be problematic. 
Not only are properly-folded scFvs notoriously difficult 
to express in E. coli [30], but the presence of an scFv on 
every copy of single-chain dimer coat protein (90 scFvs 
total) is likely to interfere with VLP assembly by steric 
crowding at the capsid’s threefold symmetry axes. To 
limit the number of scFvs per VLP, we terminated the 
coat sequence with a single amber codon. Normally, 
ribosomes would efficiently terminate to produce the 
coat protein single-chain dimer. However, in the pres-
ence of an appropriate suppressor tRNA expressed from 
a second plasmid (i.e. pNMsupA or pNMsupS), nonsense 
suppression allows production of the fusion protein. 
The ratio of coat protein to coat-scFv fusion is a func-
tion of the efficiency of the nonsense suppressor. When 
the suppression efficiency is low, the coat protein itself 
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Fig. 1 The architecture of plasmids used along with results of scFv-MS2 VLP fusion construct expression. a Schematic representation and abbrevi-
ated nucleotide sequence of pDSP62-scFv. In all cases, the specific scFv is fused in the same way to coat protein. Note the end of the MS2 coat pro-
tein sequence in blue, the amber stop codon in red, the flexible glycine linker between coat and scFv in green, and the beginning of the specific scFv 
sequence in purple. tP7 = T7 terminator (paired with leading T7 promoter). b Agarose gel stained with ethidium bromide indicating the presence 
of intact, RNA-containing VLPs in both wild-type (WT) and all fusion (M18, AF20, scFv26, scFv66) samples. c Western blot results for samples found 
in b. Proteins were separated via SDS-PAGE and then transferred to nitrocellulose for blotting. Blot was developed with rabbit anti-MS2 primary and 
goat anti-rabbit HRP-IgG secondary antibodies. Note the presence of the single-chain dimer (SCD) coat protein in all samples and a higher-weight 
band in the scFv fusion samples (scFv); this is presumed to be the scFv-coat protein fusion. Double bands in some wells are believed to be potential 
degradation products of the scFv-coat protein fusion, though their presence does not appear to affect function. pDSP62 = WT coat protein only
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is produced at high levels, but only a small percentage is 
fused to an scFv. The excess of single-chain coat protein 
thus produced co-assembles with the scFv fusion protein 
to produce a VLP that displays the antibody fragments at 
low copy number. Indeed, when the stop codon between 
coat protein and the scFv was removed, or suppressed by 
a highly efficient suppressor, a high level of the coat pro-
tein-scFv fusion was synthesized, but no VLPs were pro-
duced (not shown). Moreover, the majority of the fusion 
protein was found in the insoluble fraction of cell lysates, 
indicating a failure to properly fold. For the experiments 
described below, we used an alanine-inserting suppres-
sor tRNA described by Miller [31]. Based on the relative 
amounts of fusion and non-fusion proteins produced, we 
estimate its suppression efficiency in our system to be 
about 3%, corresponding to an average of three copies of 
coat protein-scFv fusion per assembled VLP.
Expression of scFv‑MS2 fusion VLPs
The coat protein-scFv fusions were expressed in E. 
coli and purified by size-exclusion chromatography as 
described previously [13]. A schematic representation of 
the construct used for expression and purification, along 
with some relevant features of individual constructs, are 
shown in Fig. 1a. Each recombinant produced a coat pro-
tein whose elution behavior from Sepharose CL-4B was 
consistent with a particle the size of the MS2 VLP (not 
shown). Agarose gel electrophoresis verified the produc-
tion of a particle with electrophoretic mobility very simi-
lar to that of the normal VLP. The fact that the band seen 
on the gel was susceptible to staining with ethidium bro-
mide indicates the presence of an intact, closed VLP able 
to contain RNA (Fig. 1b). The proteins were subjected to 
electrophoresis in polyacrylamide gels containing SDS 
and then blotted to a nitrocellulose membrane. Prob-
ing with anti-MS2 serum shows that most of the protein 
takes the form of the single-chain dimer, and that smaller 
amounts of the fusion proteins are produced (Fig.  1c). 
The presence of the larger species depends on the scFv 
fusion construct and is therefore most likely to represent 
the coat protein-scFv fusion. This is due to the molecu-
lar weight of the scFv, which dramatically increases the 
molecular weight of the single-chain dimer.
Functional testing of M18 VLPs
M18 is an scFv specific for the protective antigen (PA) of 
Bacillus anthracis, a widely-studied pathogen due to both 
the ease with which it can be produced and its potential 
applications as a bioweapon. To show that the scFv was 
displayed on the VLP in a functional form, we measured 
the ability of varying amounts of either wild-type (WT) 
or M18 VLPs to bind protective antigen adsorbed to the 
wells of an ELISA plate. The presence of the VLP was 
detected by reaction with rabbit anti-MS2 antibody, fol-
lowed by goat anti-rabbit IgG conjugated to HRP. After 
reaction with 2,2′-azino-bis(3-ethylbenzthiazoline-6-sul-
fonic acid) (ABTS), the wells were read at an optical den-
sity of 405  nm on a plate reader. The results are shown 
in Table  1. In spite of the relatively high backgrounds 
with control VLPs, it is clear that the M18-VLP binds the 
antigen.
Varying amounts of WT VLPs (50–25  µg, 1.2 ×  1013 
to 6  ×  1012 particles) and M18 VLPs (from 50–5  μg, 
1.2  ×  1013 to 1.2  ×  1012 particles) were incubated on 
wells to which 500  ng of anthrax protective antigen 
(APA) was adsorbed. Wells were then probed with rab-
bit anti-MS2 primary and goat anti-rabbit HRP-IgG sec-
ondary antibodies, and the developing reagent used was 
ABTS. Numbers given in the table are optical densities 
(ODs) at 405 nm.
Functional testing of AF‑20 VLPs
As a second example of scFv display on VLPs, we chose 
an antibody specific for the AF-20 antigen found on 
a wide variety of HCC. Since no soluble form of AF-20 
antigen is presently available [10], determining binding 
by ELISA was not possible. Instead, we labeled both WT 
and AF-20 VLPs with AlexaFluor 488 and compared their 
binding to Hep3B cells, which express AF-20 on their 
surfaces, with Thle-3 cells, which do not (Fig.  2). VLPs 
displaying the anti-AF-20 scFv abundantly bind Hep3B 
but not Thle-3 cells. In addition, Z-stack analysis shows 
that some of the VLPs were internalized by Hep3B cells, 
which is expected when AF-20 antigen interacts with 
AF-20 antibody [10] (not shown).
We confirmed binding to Hep3B cells by flow cytometry. 
1 ×  106 Thle-3 or Hep3B cells were exposed to increas-
ing amounts of either WT or AF-20 VLPs (4  ×  1012 to 
4  ×  1015 total particles) labeled with Alexa Fluor 488 
for 1  h at 37  °C. Cells were then pelleted, washed, fixed 
with 3.7% formaldehyde, and then resuspended in FACS 
buffer. Cell samples were immediately analyzed with a 
Table 1 ELISA results for  WT and  M18 VLPs against   
anthrax protective antigen
OD405





Volume WT VLP (μl @ 5 mg/ml)
 10 0.267
 5 0.232
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FACSCalibur flow cytometer. The mean fluorescence 
intensity (MFI) was plotted for each of the four combina-
tions of VLPs and cell types (Fig. 3a). Both WT and AF-20 
VLPs showed a lower binding affinity to Thle-3 cells. How-
ever, Hep3B cells bind the scFv-displaying particles better 
than they bind WT VLPs, especially at low concentrations 
before non-specific interactions become important due to 
extremely high ratios of particles to cells. In Fig. 3b, back-
ground binding is determined for each cell type by remov-
ing the WT VLP signal from the AF-20 VLP signal. From 
this graph, we can visually confirm that WT VLPs do not 
bind any better to Hep3B cells than to Thle-3 cells. How-
ever, AF-20 VLPs demonstrate much greater binding spec-
ificity, plateauing finally at very high particle numbers.
Functional testing of scFv26 and scFv66 VLPs
Nipah virus (NiV) is a BSL-4 agent that typically causes 
fatal respiratory and encephalitic infections in humans. 
Antibody neutralization of NiV can be conveniently 
determined, however, using a BSL-2 recombinant vesicu-
lar stomatitis virus (VSV) pseudotyped with NiV struc-
tural proteins. scFv26 is specific for Nipah G protein, 
a critical protein for viral attachment to host cells [27]. 
scFv66 is specific for the Nipah F protein, which mediates 
fusion to host cells [28]. Both of these scFvs neutral-
ize NiV by binding to and inhibiting the function of 
their cognate proteins on the surface of the virus. VLPs 
displaying either scFv26 or scFv66 were tested for their 
ability to neutralize infection of Vero cells by the afore-
mentioned pseudotyped VSV (known as NiVpp in the 
text) that had been engineered to express luciferase upon 
successful infection of cells.
Varying amounts of scFv26 or scFv66 VLPs were incu-
bated with a constant amount of virus, which was then 
used to infect Vero cells. The luciferase produced corre-
sponds to infection with the pseudotyped VSV, as only cells 
that have been infected will produce luciferase. Figure  4 
shows that both particles efficiently inhibit (though do not 
entirely eliminate) infection, although scFv26 VLPs are 
slightly better (Fig. 4a). In fact, the VLP-associated scFv26 
is nearly as effective as mAb26 itself and is far better than 
soluble scFv26 (Fig. 4b). Soluble scFv66 is an even weaker 
neutralizer than soluble scFv26, but is more effective when 
displayed on the VLP surface (Fig.  4b). The mAbs them-
selves seem to depend on their bivalency for efficient neu-
tralization. The linkage of our estimated average of three 
copies of the scFvs to each VLP apparently restores the 
valency needed for potent neutralizing activity.
Fig. 2 Confocal microscopy of AF-20-bearing VLPs to Hep3B and Thle-3 cells. Cells at 70% confluency were incubated with 10 µg (2.4 × 1012 parti-
cles) of AlexaFluor 488-labeled AF-20-bearing VLPs for 2 h at 37 °C in serum-free EMEM. Cells were then fixed with 3.7% formaldehyde and stained 
with CellTracker Red CMFDA to visualize the cytoplasm and Hoechst 33342 to visualize the genetic material in the nucleus. Cells were then imaged 
with a Zeiss LSM510 META confocal microscope. Note the abundance of AF-20-bearing VLPs bound to Hep3B but not Thle-3 cells. Examination of 
z-stacks of images also indicated some internalization of bound particles in the Hep3B sample (not shown). Scale bars 10 μm
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Discussion
In this study, we constructed four scFvs: M18, AF-20, 
scFv26, and scFv66. In all four cases, the scFv was fused 
to the coat protein of MS2 via genetic insertion and dis-
played on the surface of the MS2 VLP. In each case, we 
showed that the scFv was both present and functional on 
the surface of the VLP. We limited the number of scFvs 
on the VLP surface via a system of nonsense suppres-
sion. By separating the coat protein and the C-terminally-
fused scFv with an amber stop codon, we can control the 
number of coat-scFv fusion proteins that are created. We 
determined that roughly three copies of any given scFv 
are present on the surface of the VLP using this display 
method in our system.
We found it necessary to limit the number of scFvs dis-
played on the VLP surface because, when the scFv-MS2 
fusion is expressed at high levels, the hybrid protein fails 
to fold properly. This means that populations consisting 
entirely of fusion protein don’t make VLPs, and all of the 
fusion protein ends up in the insoluble fraction of cell 
lysates. For most applications, we suspect that the rela-
tively low valency of scFv display is a desirable charac-
teristic, since high valency may show increased avidity 
Fig. 3 Binding of WT and AF-20 VLPs to Thle-3 and Hep3B cells 
vis FACS. The key of the figure indicates which VLP and cell type 
is being analyzed. a 1 × 106 of either Thle-3 or Hep3B cells were 
incubated with increasing quantities of either WT or AF-20 AlexaFluor 
488-labeled VLPs (4 × 1012 to 4 × 1015, roughly 16 µg to 16 mg) for 
1 h at 37 °C. Cells were then fixed and washed, and mean fluorescent 
intensity (MFI) was measure via FACSCalibur. Note that neither WT nor 
AF-20 VLPs bind particularly well to Thle-3 cells (negative for AF-20 
antigen), whereas only AF-20 VLPs bind to Hep3B cells (positive for 
AF-20 antigen) until the number of particles overwhelms the system 
and creates non-specific binding effects. b For each cell type from a, 
the value obtained for WT VLPs was treated as “background” binding 
and was subtracted from the value obtained for AF-20 VLPs, which 
were considered “signal”. This aides in the visualization of increased 
specific binding of AF-20 VLPs to Hep3B cells before total particle 
number becomes too large and the signal plateaus
Fig. 4 Neutralization of Nipah-pseudotyped VSV (NiVpp). a Varying 
concentrations of VLPs (0.1 μg/ml to 1 mg/ml, 1.3 × 108 to 1.3 × 1012 
total particles/well) were incubated with enough NiVpp (designed 
to express Nipah G- and F-proteins and express Renilla luciferase) to 
produce 300,000 relative light units (RLU) in control wells in this assay. 
This mixture was then used in an infection of Vero cells, and RLU due 
to infection of cells by non-neutralized VSV (and are thus producing 
luciferase) are measured in each case. There is concentration-depend-
ent neutralization in both cases, though neutralization by scFv26 
VLPs is slightly better than neutralization by scFv66 VLPs. b A constant 
1.5 ng/μl concentration (corresponding to ~2.0 × 1010 particles for 
the scFv-VLP fusions) of each potential neutralizer of NiVpp (shown 
on the horizontal axis) was incubated with NiVpp and used in an 
infection of Vero cells as in a. RLU was again measured from luciferase 
expression to determine neutralization. mAb26 G-specific monoclonal 
antibody (scFv parent), scFv26 NiVG-specific scFv, scFv66 NiVF-specific 
scFv, VLP-scFv26/scFv66 the two scFvs fused to MS2 VLPs
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for normally low-affinity targets, thus increasing non-
specific binding. However, it may be desirable in some 
instances to present the scFv at high copy numbers. In 
such cases, it would be necessary to utilize better-folding 
scFv variants, or E. coli strains that are better adapted to 
the folding of heterologous proteins. For example, the 
cytoplasm of E. coli is normally reducing, meaning that 
the disulfide bonds necessary for correct folding and sta-
bility of antibodies are unable to form. Mutant strains 
that produce an oxidizing environment seem to facilitate 
antibody folding and might also enhance the folding of 
the coat-scFv fusion protein [32]. Strains that overpro-
duce specific chaperone proteins might also be useful 
[33]. It would also be possible to display additional cop-
ies of the scFv on the VLP surface by means of chemical, 
rather than genetic, linkage. This destroys the pheno-
type-to-genotype link that genetic insertion affords, but 
once the sequence of a particular scFv is known, it can 
be synthesized in large quantities outside of the system 
and then attached to the surface of the VLP. Alternatively, 
it may be desirable to utilize a different coat protein as 
the basis of the VLP. For example, the coat protein of the 
Acinetobacter phage AP205 seems to be more tolerant of 
fusions at its termini. It has already been used for display 
of a few larger peptides and even of some small proteins, 
including an affibody [34, 35].
The ability to engineer the display of diverse scFvs on 
VLPs suggests a number of potential applications, includ-
ing the targeted delivery of drugs and imaging agents. 
Nanoparticles possessing certain binding specificities 
should also find applications in diagnostics, as molecu-
lar detectors, and as potential treatments for disease. For 
example, as we showed here, VLPs displaying anti-NiV 
scFvs can potentially neutralize authentic NiV because 
they are capable of neutralizing NiV-pseudotyped VSV 
(NiVpp) with potencies near those of the correspond-
ing monoclonal antibodies themselves. Presumably, this 
is due to the avidity effects associated with simultaneous 
display of several copies of the scFv on each VLP. In addi-
tion, the larger size of the VLP (when compared to the 
Fc portion of an antibody) may help two (or more) anti-
body binding sites gain access to adjacent proteins on the 
virus surface. Importantly, there may be additional room 
for improvement with these results, such as optimization 
of scFv copy number on the VLP surface. Such optimiza-
tions could lead to the scFv-VLP particles becoming even 
more potent neutralizers of NiV.
Additionally, as we observed in with the AF-20 VLPs, 
the scFv-MS2 fusion can be labeled with a dye (e.g. an 
Alexa Fluor NHS ester) without disrupting the function 
of the scFv. In this way, the VLPs displaying anti-NiV 
scFvs could also be used as detection reagents for NiV-
infected cells, which display Nipah proteins on their 
surfaces as the virus buds. Finally, using the MS2 VLP has 
several advantages as a targeted drug delivery vehicle. It 
has a large interior volume, which can be loaded with a 
variety of molecular cargos. Indeed, several groups have 
already demonstrated the ability of MS2 VLPs to accept a 
variety of molecular cargos and then deliver them to spe-
cific cell types when decorated with appropriate targeting 
peptides or RNA aptamers [6–8]. The ability to engineer 
the display of a variety of different scFvs should allow the 
use of the huge collection of cell-specific antibodies now 
available to serve as the basis for generation of imaging 
and drug delivery vehicles for diverse cell types. Depend-
ing on the receptor targeted by the scFv, a wide variety of 
cell types and cell entry pathways could be targeted.
Another natural use for the display of scFvs on the sur-
face of MS2 VLPs is the creation of scFv libraries that can 
be used in affinity selection experiments to discover novel 
scFv binders to a specific target. There are many systems 
already in the literature for the display of scFvs, including 
mammalian cells [36] and yeast [37]; several groups have 
even created scFv libraries for display on filamentous 
phage [38]. However, the MS2 system has several advan-
tages over these systems. The first is its simplicity, owing 
to the nature of the VLP itself. The VLP is comprised of a 
single protein that can be expressed off of a plasmid, and 
this expression need not happen within a living cell. This 
means that libraries of scFvs displayed on the surface of 
MS2 VLPs could theoretically be transcribed and trans-
lated entirely in vitro, which would allow for even greater 
library complexities and speed/scale of production. In 
addition, owing to the properties of the VLP discussed 
above, the scFv-VLP fusion could be used directly after 
affinity selection for e.g. imaging or potential targeted 
delivery; there is no need to move to a different expres-
sion platform.
Conclusions
Overall, we believe that the work presented here has 
direct implications in the field of nanobiotechnology. 
We have here displayed four different functional scFvs 
on the surface of the MS2 VLP, thus providing evidence 
of the suitability of the MS2 VLP platform to display 
genetically-fused scFvs. This allows for many uses of the 
scFv-MS2 VLP, including as detection reagents, imaging 
agents, and therapeutics. This work also paves the way 
for future work with libraries of scFvs displayed on the 
MS2 surface, allowing for biopanning and the discovery 
of novel scFvs to a target that can be utilized immediately 
within the platform that they were discovered.
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